File:Vaccines-09-00065-g002.webp
From Wikimedia Commons, the free media repository
Jump to navigation
Jump to search
Size of this PNG preview of this WEBP file: 800 × 593 pixels. Other resolutions: 320 × 237 pixels | 640 × 474 pixels | 1,024 × 759 pixels | 1,280 × 949 pixels | 2,560 × 1,898 pixels | 3,482 × 2,581 pixels.
Original file (3,482 × 2,581 pixels, file size: 2.24 MB, MIME type: image/webp)
File information
Structured data
Captions
Summary
[edit]DescriptionVaccines-09-00065-g002.webp |
English: mRNA lipid nanoparticle assembly is achieved by (A) rapid mixing in a microfluidic or T-junction mixer of four lipids (ionizable lipid, DSPC, cholesterol, PEG–lipid) in ethanol with mRNA in an aqueous buffer near pH4. (B) When the ionizable lipid meets the aqueous phase, it becomes protonated at a pH ~5.5, which is intermediate between the pKa of the buffer and that of the ionizable lipid. (C) The ionizable lipid then electrostatically binds the anionic phosphate backbone of the mRNA while it experiences hydrophobicity in the aqueous phase, driving vesicle formation and mRNA encapsulation. (D) After initial vesicle formation, the pH is raised by dilution, dialysis or filtration, which results in the neutralization of the ionizable lipid, rendering it more hydrophobic and thereby driving vesicles to fuse and causing the further sequestration of the ionizable lipid with mRNA into the interior of the solid lipid nanoparticles. The PEG–lipid content stops the fusion process by providing the LNP with a hydrophilic exterior, determining its thermodynamically stable size, and the bilayer forming DSPC is present just underneath this PEG–lipid layer. |
Date | |
Source | Buschmann, M.D.; Carrasco, M.J.; Alishetty, S.; Paige, M.; Alameh, M.G.; Weissman, D. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines 2021, 9, 65. https://doi.org/10.3390/vaccines9010065 |
Author | Michael D. Buschmann, Manuel J. Carrasco, Suman Alishetty, Mikell Paige, Mohamad G. Alameh, and Drew Weissman |
Licensing
[edit]This file is licensed under the Creative Commons Attribution 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 09:31, 15 August 2021 | 3,482 × 2,581 (2.24 MB) | Guest2625 (talk | contribs) | Uploaded a work by Michael D. Buschmann, Manuel J. Carrasco, Suman Alishetty, Mikell Paige, Mohamad G. Alameh, and Drew Weissman from Buschmann, M.D.; Carrasco, M.J.; Alishetty, S.; Paige, M.; Alameh, M.G.; Weissman, D. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines 2021, 9, 65. https://doi.org/10.3390/vaccines9010065 with UploadWizard |
You cannot overwrite this file.
File usage on Commons
There are no pages that use this file.
File usage on other wikis
The following other wikis use this file:
- Usage on cs.wikipedia.org
- Usage on en.wikipedia.org
- Usage on gl.wikipedia.org
- Usage on he.wikipedia.org
- Usage on ka.wikipedia.org
Hidden category: